Lagneaux L, Delforge A, Bron D, Bosmans E, Stryckmans P
Service de Médecine Interne et Laboratoire d'Investigation Clinique Henri Tagnon, Institut J. Bordet, Brussels, Belgium.
Leuk Lymphoma. 1995 Mar;17(1-2):127-33. doi: 10.3109/10428199509051712.
We studied the production of cytokines (G-CSF, GM-CSF, IL-6, LIF and IL-10) by bone marrow stromal cells of five untreated patients with B-CLL, in Rai stage 0, I and II, and of 8 healthy subjects. The production of G-CSF, GM-CSF, LIF and IL-10 did not differ significantly between controls and B-CLL patients. However, the ability of stromal cells to release IL-6 in response to LPS was decreased in all patients: 36 +/- 5 ng/ml versus 123 +/- 47 ng/ml for normal controls (p < 0.004). Moreover, a soluble activity that inhibited hematopoietic colony formation was detected in B-CLL stromal cell conditioned media. Some potential inhibitors were envisaged and the results indicated an increased production of TGF-beta by B-CLL stromal cells compared to normal stromal cells (respectively 53 +/- 10 versus 15 +/- 4 ng/ml, p < 0.03). The reduced capacity of B-CLL stromal cells to produce IL-6 was associated with this excessive release of TGF-beta; indeed, addition of anti-TGF-beta neutralizing antibody to B-CLL stromal cells, before LPS stimulation, totally normalized the production of IL-6. TGF-beta and IL-6 were also measured in serum samples from normal subjects and B-CLL patients. No significant difference was seen in the production of total TGF-beta (bioactive and latent forms) between normal and B-CLL sera but the mean level of bioactive protein in B-CLL sera was increased in comparison with normal sera (1.74 +/- 0.44 versus 0.67 +/- 0.2 ng/ml, p < 0.04).(ABSTRACT TRUNCATED AT 250 WORDS)
我们研究了5例处于Rai分期0、I和II期的未经治疗的B细胞慢性淋巴细胞白血病(B-CLL)患者以及8名健康受试者的骨髓基质细胞产生细胞因子(粒细胞集落刺激因子(G-CSF)、粒细胞-巨噬细胞集落刺激因子(GM-CSF)、白细胞介素-6(IL-6)、白血病抑制因子(LIF)和白细胞介素-10(IL-10))的情况。对照组和B-CLL患者之间G-CSF、GM-CSF、LIF和IL-10的产生没有显著差异。然而,所有患者的基质细胞对脂多糖(LPS)产生反应释放IL-6的能力均下降:正常对照组为123±47 ng/ml,而患者组为36±5 ng/ml(p<0.004)。此外,在B-CLL基质细胞条件培养基中检测到一种抑制造血集落形成的可溶性活性物质。设想了一些潜在的抑制剂,结果表明与正常基质细胞相比,B-CLL基质细胞产生转化生长因子-β(TGF-β)增加(分别为53±10 ng/ml和15±4 ng/ml,p<0.03)。B-CLL基质细胞产生IL-6的能力降低与TGF-β的过度释放有关;事实上,在LPS刺激前向B-CLL基质细胞中添加抗TGF-β中和抗体可使IL-6的产生完全恢复正常。还检测了正常受试者和B-CLL患者血清样本中的TGF-β和IL-6。正常血清和B-CLL血清中总TGF-β(生物活性和潜伏形式)的产生没有显著差异,但与正常血清相比,B-CLL血清中生物活性蛋白的平均水平有所升高(分别为1.74±0.44 ng/ml和0.67±0.2 ng/ml,p<0.04)。(摘要截断于250字)